Feb 5, 2019

A vaccine is Pfizer's best-selling drug

Expand chart
Data: Company documents; Chart: Andrew Witherspoon/Axios

Over the past 4 years, the product that generated the most sales for Pfizer wasn't one of its household names, like Lyrica, Lipitor or Viagra. It was Prevnar 13, a vaccine that protects against pneumonia and other infections.

The bottom line: Pfizer has collected $23.4 billion in Prevnar 13 sales since 2015, including $5.8 billion last year. The pharmaceutical giant got a big revenue boost in 2015, after the federal government recommended the vaccine for people older than 65 and required insurance to cover it.

Details: Before 2015, most of Pfizer's Prevnar 13 revenue came from international markets.

  • But the seal of approval from the Centers for Disease Control and Prevention in late 2014 prompted U.S. seniors to get the vaccine, which most commonly was given to children younger than 2.
  • Pfizer commands higher prices for the drug in the U.S. The price of a single Prevnar 13 shot this year, before taking out rebates and discounts, is about $195 — a 5% increase from 2018 and 79% higher than its list price from 2010.
  • The patent for Prevnar 13 doesn't expire until 2026, several years after some of Pfizer's other growing medications, like Ibrance and Xeljanz, will have lost their patent protection. (Lyrica, Lipitor and Viagra are already off-patent.)

Go deeper: The rising price of the pneumococcal vaccine is angering doctors, Kaiser Health News reports.

Go deeper

A surprising flu strain is responsible for most pediatric deaths this season

Influenza vaccination utensils. Photo: Christoph Soeder/picture alliance via Getty Images

A surprisingly early strain of the influenza B virus is responsible for 21 of the 32 pediatric deaths in this flu season, according to new data from the Centers for Disease Control and Prevention.

Between the lines: Influenza B hasn't been a main cause for sickness in the U.S. for 27 years. It isn't as much of a risk to senior citizens, but tends to cause more complications in young children.

Go deeperArrowJan 13, 2020

Most Americans think measles vaccine has "very high" preventative care benefits

A vial containing the MMR vaccine. Photo: Mel Melcon/Los Angeles Times via Getty Images

56% of Americans believe the measles vaccine has "very high" preventative care benefits — an 11-point increase since 2016, according to data out Tuesday from the Pew Research Center.

The big picture: While overall approval of the vaccine (88%) has remained unchanged, Pew credits the increase in perceived preventative health benefits to improved awareness of how measles outbreaks have become a public health problem.

Go deeper: America's dangerous backslide on infectious diseases

Drugmakers opt to mine medical data in lieu of lengthy clinical trials

Big drugmakers Pfizer, Johnson & Johnson and Amgen have submitted data-mining analyses of electronic medical records to the Food and Drug Administration to help expedite the approval of new or improved medicines, the Wall Street Journal reports.

Why it matters: So far, parsing patient data instead of carrying out long clinical trials has cut costs and shortened drug-development times for breast cancer, bladder cancer and leukemia drugs.

Go deeperArrowDec 23, 2019